Checkpoint Therapeutics Inc (NASDAQ:CKPT)

5.16
Delayed Data
As of Jan 26
 0.00 / 0.00%
Today’s Change
3.56
Today|||52-Week Range
27.00
+0.98%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$51.8M

Company Description

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Contact Information

Checkpoint Therapeutics, Inc.
95 Sawyer Road
Waltham Massachusetts 02453
P:(781) 652-4500
Investor Relations:

Employees

Shareholders

Other institutional8.58%
Mutual fund holders5.74%
Individual stakeholders20.33%

Top Executives

James F. OlivieroPresident, Chief Executive Officer & Director
William Garrett GrayChief Financial Officer, Secretary & Treasurer
Jaclyn JaffeHead-Investor Relations